ATM and metastatic melanoma: Nevertheless, findings from the ATM biomarker-matched cohort reflect the promising antitumor activity, notably in patients with alterations in the DDR pathway, seen in a study of durvalumab–ceralasertib in patients with advanced/metastatic melanoma following anti-PD-1 failure64.